Suspected side effects should be reported via the MHRA Yellow Card scheme (yellowcard.mhra.gov.uk)
In addition to the STEP trials, real-world studies and independent reviews further support the effectiveness of a variety of GLP-1 receptor agonists for weight management, with weight loss typically ranging from 5% to 15% depending on dose, duration, and adherence.28,29 A retrospective, noninterventional drug utilization cohort study in the United Kingdom evaluated the use of different varieties of liraglutide for weight management purposes.30 Among 604 individuals using Saxenda (liraglutide 3 g) and 4,853 individuals using Victoza (liraglutide 1.2 mg/1.8 mg), most were able to achieve 5% weight loss within 24 weeks.30 Emerging data on tirzepatide has also shown even greater weight reductions (up to 21% over 72 weeks) over other GLP-1s, as well as improved quality of life.31,32 Together, these findings show the support GLP-1s can provide in long-term weight management
Ferroptosis and metastasis: Molecular checkpoints, microenvironmental dynamics, and therapeutic opportunities
17 Further tips and guidelines for managing obesity in women have been summarized by Tauqeer et al
